North America Antibody Drug Conjugates Market
市场规模（十亿美元）
CAGR :
% 
USD
4.81 Billion
USD
14.62 Billion
2024
2032
 Forecast Period |
2025 –2032 |
 Market Size (Base Year) |
USD 4.81 Billion |
 Market Size (Forecast Year) |
USD 14.62 Billion |
 CAGR |
% |
| Major Markets Players |
|
北美抗體藥物偶聯物 (ADC) 市場細分，按產品（Enhertu、Kadcyla、Trodelvy、Polivy、Adcetris、Padcev、Besponsa、Elahere、Zylonta、Mylotarg、Tivdak 等）、抗原組成（HER2 受體、Trop-2、CD79B、CD30、Nectin 4、CD22、CD19、CD33、組織因子等）、抗體成分（第三代 ADC、第二代 ADC、第四代 ADC 和第一代 ADC）、連接子成分（可裂解連接子和不可裂解連接子）、細胞毒性有效載荷或彈頭成分（DNA損傷劑和微管破壞劑）、連接子技術（勝肽連接子、硫醚連接子、腙連接子和二硫鍵連接子）、偶聯技術（位點特異性結合和化學結合）、適應症（乳腺癌、血癌（白血病、淋巴瘤）、肺癌、婦科癌症、胃腸道癌症、泌尿生殖系統癌症等）、最終用戶（醫院、專科診所2032 年
北美抗體藥物偶聯物（ADC）市場規模
- 2024 年北美抗體藥物偶聯物 (ADC) 市場規模為48.1 億美元 ，預計 到 2032 年將達到 146.2 億美元，預測期內 複合年增長率為 14.90%。
- 市場成長主要得益於癌症發病率的上升，以及越來越多地採用具有更高療效和更低毒性的標靶療法，這推動了向精準腫瘤學的轉變
- 此外，不斷成長的研發投入、強勁的臨床管線以及有利的監管措施正在加速ADC的開發和商業化。這些因素共同鞏固了ADC作為該地區生物製藥格局關鍵組成部分的地位，從而顯著促進了該行業的成長。
北美抗體藥物偶聯物（ADC）市場分析
- 抗體藥物偶聯物 (ADC) 結合了單株抗體的標靶能力和化療藥物的細胞毒性，由於其精準度高、副作用小、臨床成功率高，在北美（尤其是美國、加拿大和墨西哥）的癌症治療中正成為不可或缺的治療手段
- ADC 需求的成長主要源於癌症發生率的上升、對個人化醫療的日益關注以及該地區對腫瘤學研究和臨床開發的投資不斷增加
- 美國在北美抗體藥物偶聯物 (ADC) 市場佔據主導地位，2024 年其收入份額最大，為 82.8%，這得益於其高度先進的醫療保健體系、強大的生物製藥研發投資以及大量積極開發和商業化 ADC 療法的大型製藥公司
- 受癌症意識增強、醫療保健管道暢通以及跨境臨床研究合作日益增多的推動，加拿大預計將成為北美抗體藥物偶聯物 (ADC) 市場成長最快的國家
- 乳癌領域在北美抗體藥物偶聯物 (ADC) 市場佔據主導地位，2024 年的市佔率為 40.2%，這得益於 HER2 標靶 ADC 的臨床成功以及三陰性乳癌等侵襲性乳癌亞型治療的持續進展
報告範圍和北美抗體藥物偶聯物（ADC）市場細分
|
屬性 |
北美抗體藥物偶聯物（ADC）市場關鍵洞察 |
|
涵蓋的領域 |
|
|
覆蓋國家 |
北美洲
|
|
主要市場參與者 |
|
|
市場機會 |
|
|
加值資料資訊集 |
除了對市場價值、成長率、細分、地理覆蓋範圍和主要參與者等市場情景的洞察之外，Data Bridge Market Research 策劃的市場報告還包括深入的專家分析、定價分析、品牌份額分析、消費者調查、人口統計分析、供應鏈分析、價值鏈分析、原材料/消耗品概述、供應商選擇標準、PESTLE 分析、波特分析和監管框架。 |
北美抗體藥物偶聯物（ADC）市場趨勢
“位點特異性結合和連接技術的發展”
- 北美 ADC 市場的一個重要且加速發展的趨勢是位點特異性結合方法和下一代連接子技術的不斷發展，從而能夠提高治療精準度、改善安全性，並提高對各種癌症類型的療效
- 例如，Seagen Inc. 專有的連接體-有效載荷技術在 ADC 的臨床和商業成功中發揮了關鍵作用，例如 Adcetris，該藥物靶向 CD30 陽性淋巴瘤，穩定性更高，脫靶毒性更低。同樣，由第一三共和阿斯利康開發的 HER2 靶向 ADC Enhertu 採用了可裂解的連接體，具有較高的藥物抗體比，這促使其在 HER2 低水平乳腺癌治療中獲得批准並得到更廣泛的應用。
- 這些進展使 ADC 能夠治療先前難以治療的實體腫瘤，從而將其應用範圍拓展至血液系統惡性腫瘤之外。此外，與生物標記檢測的整合使腫瘤學家能夠更好地選擇患者群體，從而改善治療效果。
- 美國公司正在大力投資擴大針對更廣泛腫瘤抗原的 ADC 產品線，其中多個 ADC 正在進入後期臨床試驗階段
- 這種高度特異性、穩定性和可擴展性的 ADC 平台趨勢正在重塑整個北美的腫瘤治療模式，生物製藥公司競相開發具有優化療效和耐受性的新型 ADC 候選藥物
北美抗體藥物偶聯物（ADC）市場動態
司機
“癌症盛行率上升和強大的生物製藥研發管道”
- 美國、加拿大和墨西哥的癌症發生率不斷上升，加上製藥公司積極關注標靶治療和生物製劑，是北美 ADC 市場的主要驅動力
- 例如，美國癌症協會估計，2024年美國將新增超過190萬例癌症病例，將導致對更有效、更個人化的腫瘤治療（例如ADC）的需求不斷增長。輝瑞、吉利德科學和ImmunoGen等公司處於創新前沿，擁有多個處於臨床或商業階段的ADC。
- 策略合作和高價值收購進一步推動了市場發展。值得注意的是，輝瑞於2023年收購Seagen，進一步強化了ADC技術在拓展腫瘤藥物研發管線的重要性。
- 此外，美國的支持性監管環境，以 FDA 的快速審批和突破性認定為特徵，正在加速 ADC 的開發和商業化
- 隨著強勁的投資流、積極的臨床研究以及腫瘤學家和患者意識的提高，ADC 正在成為北美癌症治療策略中不可或缺的一部分，推動市場持續成長勢頭
克制/挑戰
“開發成本高且監管複雜”
- 由於製造流程複雜、監管要求嚴格，ADC 開發成本高昂，對北美市場的廣泛擴張構成了重大挑戰
- 例如，ADC 的生產涉及複雜的步驟，包括抗體工程、穩定的連接體設計和精確的藥物結合，所有這些都需要專門的基礎設施和品質控制，從而導致生產成本上升
- 美國FDA和加拿大衛生部等監管機構要求審批時提供嚴格的數據，尤其是在藥物動力學、毒性和生產一致性方面。這通常會導致生物製藥公司開發週期延長，並投入更多資源。
- 規模較小的生物技術公司在沒有大量資金或合作夥伴關係的情況下，可能難以擴大生產規模或滿足監管要求。在加拿大和墨西哥，報銷限制和來自公共醫療體系的定價壓力也可能限制ADC的可及性。
- 透過流程優化、早期監管參與以及創新定價和存取模式來克服這些挑戰對於推動北美地區更廣泛的採用和長期市場成長至關重要
北美抗體藥物偶聯物（ADC）市場範圍
市場根據產品、抗原成分、抗體組成、連接體成分、細胞毒性有效載荷、連接體技術、結合技術、適應症、最終用戶和分銷管道進行細分。
- 按產品
北美抗體藥物偶聯物 (ADC) 市場按產品細分，包括 Enhertu、Kadcyla、Trodelvy、Polivy、Adcetris、Padcev、Besponsa、Elahere、Zylonta、Mylotarg、Tivdak 和其他。 Enhertu 細分市場在 2024 年佔據市場主導地位，收入份額最高，這得益於其在 HER2 低表達乳腺癌中的強大臨床療效以及在多種實體瘤中的獲批不斷擴大。其創新的連接體-有效載荷設計和高藥物抗體比可提供卓越的治療效果，從而促進其廣泛應用。
預計Elahere領域將在2025年至2032年間實現最快的成長，這得益於其近期獲準用於治療葉酸受體α陽性的卵巢癌，以及越來越多的臨床證據支持其療效。隨著越來越多的婦科腫瘤醫師將Elahere納入治療方案，預計其在特定適應症中的份額將迅速擴大。
- 依抗原成分
根據抗原成分，北美抗體藥物偶聯物 (ADC) 市場細分為 HER2 受體、Trop-2、CD79B、CD30、Nectin 4、CD22、CD19、CD33、組織因子和其他。由於美國和加拿大 HER2 陽性和 HER2 低表達乳癌病例的盛行率較高，以及 Enhertu 和 Kadcyla 等 HER2 標靶 ADC 的成功，HER2 受體細分市場在 2024 年佔據了最大的市場份額。
預計 Trop-2 領域將在 2025 年至 2032 年間見證最快的複合年增長率，這得益於 Trodelvy 等針對 Trop-2 的 ADC 的持續發展，這些 ADC 在三陰性乳腺癌和尿路上皮癌中已顯示出良好的治療效果。
- 按抗體成分
根據抗體成分，北美抗體藥物偶聯物 (ADC) 市場細分為第一代 ADC、第二代 ADC、第三代 ADC 和第四代 ADC。第三代 ADC 在 2024 年佔據市場主導地位，這得益於其更高的穩定性、位點特異性偶聯能力以及更低的全身毒性。
第四代 ADC 領域預計將在預測期內以最高速度成長，這得益於其創新的有效載荷輸送系統和雙重作用機制，擴大了多種實體腫瘤適應症的治療潛力。
- 按連結器組件
根據連接子類型，北美抗體藥物偶聯物 (ADC) 市場可細分為可裂解連接子和不可裂解連接子。可裂解連接子細分市場在 2024 年佔據了最大的市場收入份額，這得益於其能夠透過酶促或 pH 敏感機制將細胞毒性藥物釋放到目標細胞中，從而提高療效，同時最大程度地減少脫靶效應。
不可裂解連接體部分預計在預測期內將穩定成長，這在控制藥物釋放和細胞內穩定性至關重要的血液系統癌症中是首選。
- 依細胞毒性有效載荷或彈頭組件
根據細胞毒性有效載荷，北美抗體藥物偶聯物 (ADC) 市場細分為 DNA 損傷劑和微管破壞劑。微管破壞劑在 2024 年佔據市場主導地位，這主要得益於其在已批准的 ADC 中的廣泛應用，例如 Kadcyla 和 Adcetris，這些 ADC 可有效靶向分裂中的腫瘤細胞。
預計 DNA 損傷劑領域將在預測期內以最快的速度成長，這得益於拓樸異構酶抑制劑的創新以及 Enhertu 和 Elahere 等新型 ADC 的良好結果。
- 由 Linker Technology 提供
根據連接體技術，北美抗體藥物偶聯物 (ADC) 市場細分為勝肽連接體、硫醚連接體、腙連接體和二硫鍵連接體。肽連接體在 2024 年佔據最高份額，因為它們能夠在腫瘤微環境中進行酶促裂解，確保藥物僅在目標位點激活。
二硫鍵連接體由於其氧化還原敏感特性，預計在預測期內將出現顯著增長，這種特性可以在循環穩定性和癌細胞內有效釋放藥物之間取得平衡。
- 透過共軛技術
根據偶聯技術，北美抗體藥物偶聯物 (ADC) 市場細分為位點特異性偶聯和化學偶聯。位點特異性偶聯由於其對藥物抗體比例的控制更強，且生產一致性更高，在 2024 年佔據了市場主導地位。
預計化學共軛領域將在預測期內出現最快的增長，特別是早期 ADC 和依賴成熟的化學接頭-有效載荷方法的正在進行的開發項目。
- 按適應症
根據適應症，北美抗體藥物偶聯物 (ADC) 市場細分為乳腺癌、血癌（白血病、淋巴瘤）、肺癌、婦科癌、胃腸道癌、泌尿生殖系統癌和其他。乳癌領域佔據市場主導地位，2024 年收入份額最高，達到 40.2%，這得益於美國乳癌的高負擔以及 Enhertu 和 Kadcyla 等 ADC 在 HER2 陽性和 HER2 低陽性病例中的臨床成功。
由於針對 HER3、Trop-2 和其他針對非小細胞肺癌 (NSCLC) 的新型抗原的 ADC 臨床試驗不斷擴大，預計肺癌領域將在預測期內出現快速增長。
- 按最終用戶
根據最終用戶，北美抗體藥物偶聯物 (ADC) 市場細分為醫院、專科中心、診所、門診中心、家庭醫療保健和其他。 2024 年，醫院市場佔據主導地位，得益於 ADC 療法的集中管理以及腫瘤專科醫生和輸液服務的便利性。
預計專科中心領域將在 2025 年至 2032 年間實現最快增長，這主要得益於對門診癌症護理、個人化醫療和綜合腫瘤服務的需求不斷增長。
- 按分銷管道
根據分銷管道，北美抗體藥物偶聯物 (ADC) 市場細分為直接招標、零售和其他。 2024 年，直接招標市場佔據最大份額，因為大多數 ADC 療法都是由醫院和醫療機構透過政府和機構招標直接採購的。
預計零售銷售部分將在預測期內逐步增長，特別是對於自我管理或家庭輸液的 ADC，作為新興的以患者為中心的治療模式的一部分
北美抗體藥物偶聯物（ADC）市場區域分析
- 美國在北美 ADC 市場佔據主導地位，2024 年其收入份額最高，為 82.8%，這得益於其高度先進的醫療保健體系、強大的生物製藥研發投入以及大量積極開發和商業化 ADC 療法的大型製藥公司
- 美國醫療保健提供者越來越青睞 ADC，因為它們能夠提供標靶治療，且全身副作用較少，特別是對於 HER2 低乳癌和晚期尿路上皮癌等難治性癌症
- 先進的研發基礎設施、大量的腫瘤學資金以及 FDA 加速審批的優惠途徑進一步支持了這一主導地位，使美國成為該地區 ADC 創新和臨床部署的中心樞紐
美國抗體藥物偶聯物（ADC）市場洞察
2024年，美國北美抗體藥物偶聯物 (ADC) 市場佔據北美地區最大收入份額，達82.3%，這得益於美國較高的癌症發病率、對腫瘤研發的大力投入以及在生物製藥創新領域的領先地位。美國針對實體腫瘤和血液腫瘤的ADC臨床試驗和FDA審批數量迅速成長。精準醫療需求的不斷增長以及監管機構對加速審批的積極支持，正在加速市場應用。此外，生技公司與大型製藥公司之間建立的牢固合作關係，例如輝瑞收購Seagen，正在鞏固美國在ADC開發和商業化領域的主導地位。
加拿大抗體藥物偶聯物（ADC）市場洞察
預計加拿大北美抗體藥物偶聯物 (ADC) 市場在整個預測期內將保持穩定的複合年增長率，這得益於癌症認知度的提高以及先進腫瘤療法的可及性。加拿大的全民健保體系和針對新型生物製劑的積極報銷政策，正在促進醫院和專科腫瘤中心對 ADC 的採用。此外，領先的癌症研究機構的存在以及日益增多的國際臨床試驗參與度也促進了市場的發展。與美國公司的持續合作以及有利的監管框架預計將進一步刺激 ADC 在加拿大醫療保健領域的普及和應用。
墨西哥抗體藥物偶聯物（ADC）市場洞察
預計墨西哥北美抗體藥物偶聯物 (ADC) 市場在預測期內將以顯著的複合年增長率增長，這得益於癌症發病率的上升、醫療基礎設施的改善以及創新生物療法可及性的提升。墨西哥政府致力於實現癌症治療的現代化，並擴大標靶治療的可及性，這正在推動 ADC 的普及。此外，跨國製藥公司與本地經銷商之間的合作也促進了市場滲透。隨著診斷技術、患者認知度和治療可及性的不斷提高，墨西哥預計將成為北美 ADC 市場日益增長的貢獻者。
北美抗體藥物偶聯物（ADC）市場份額
北美抗體藥物偶聯物（ADC）產業主要由知名公司主導，包括：
- 阿斯特捷利康（英國）
- F. Hoffmann-La Roche Ltd（瑞士）
- BioNTech SE（德國）
- ADC Therapeutics SA（瑞士）
- 葛蘭素史克公司（英國）
- Mablink Bioscience SAS（法國）
- Synaffix BV（荷蘭）
- Seagen Inc.（美國）
- 第一三共株式會社（日本）
- 輝瑞公司（美國）
- 吉利德科學公司（美國）
- 艾伯維公司（美國）
- 安進公司（美國）
- ImmunoGen公司（美國）
- 武田藥品工業株式會社（日本）
- 皮埃爾法伯實驗室（法國）
- Philogen SpA（義大利）
- 索比（瑞典）
- 賽多利斯股份公司（德國）
- 拜耳公司（德國）
北美抗體藥物偶聯物 (ADC) 市場的最新發展是什麼？
- 2023年12月，美國食品藥物管理局（FDA）批准了ImmunoGen公司的Elahere（mirvetuximab soravtansine-gynx），用於治療葉酸受體α陽性、鉑類抗藥性的上皮性卵巢癌。這一里程碑標誌著ADC治療領域的顯著拓展，為難治性癌症亞型提供了一種新的治療選擇。此核准彰顯了FDA對快速審批創新生物製劑的持續支持，並反映了ADC在實體腫瘤中臨床驗證的不斷增加。
- 2023年11月，輝瑞完成了以430億美元收購領先的ADC創新公司Seagen Inc.的交易。此次策略性收購將整合Seagen先進的ADC平台和後期研發管線，包括Padcev和Tivdak等產品，進而增強輝瑞的腫瘤產品組合。此次收購凸顯了ADC在癌症治療中日益增長的重要性，並強化了大型製藥公司為確保下一代標靶療法而進行大規模投資的趨勢。
- 2023年10月，吉利德科學公司宣布Trodelvy（sacituzumab govitecan-hziy）在HR陽性、HER2陰性轉移性乳癌的III期臨床試驗結果呈陽性。數據顯示，該藥物顯著改善了患者的無惡化存活期，支持Trop-2靶向ADC的更廣泛應用。這項進展反映了北美在臨床研究領域的領先地位，以及ADC在高發生率癌症適應症領域的不斷擴展。
- 2023年9月，艾伯維公司與臨床階段生物技術公司DualityBio達成策略合作，利用DualityBio專有的偶聯平台共同開發多個ADC候選藥物。該協議包含高達18億美元的里程碑付款，凸顯了人們對新型連接子技術和位點特異性偶聯方法日益增長的興趣，這些方法旨在提高療效和安全性。此次合作鞏固了北美作為ADC創新和全球生物製藥合作中心的地位。
- 2023年7月，Mersana Therapeutics啟動了其領先的ADC候選藥物UpRi的II期臨床試驗，該藥物靶向治療卵巢癌的NaPi2b，試驗地點遍布美國各大學術癌症中心。這項進展反映了北美生技公司持續致力於開發針對特定癌症標靶的首創ADC，標誌著該地區臨床研發管線蓬勃發展且競爭激烈。
SKU-
Get online access to the report on the World's First Market Intelligence Cloud
- Interactive Data Analysis Dashboard
- Company Analysis Dashboard for high growth potential opportunities
- Research Analyst Access for customization & queries
- Competitor Analysis with Interactive dashboard
- Latest News, Updates & Trend analysis
- Harness the Power of Benchmark Analysis for Comprehensive Competitor Tracking
目录
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF NORTH AMERICA ANTIBODY DRUG CONJUGATES (ADC) MARKET
1.4 CURRENCY AND PRICING
1.5 LIMITATIONS
1.6 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 DBMR TRIPOD DATA VALIDATION MODEL
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.6 MULTIVARIATE MODELLING
2.7 MARKET APPLICATION COVERAGE GRID
2.8 PRODUCT LIFELINE CURVE
2.9 DBMR MARKET POSITION GRID
2.1 VENDOR SHARE ANALYSIS
2.11 SECONDARY SOURCES
2.12 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 PESTAL ANALYSIS
4.2 PORTER’S FIVE FORCES
4.3 PESTEL ANALYSIS
5 COST STRUCTURE ANALYSIS OF ANTIBODY-DRUG CONJUGATE (ADC) MANUFACTURING
5.1 ANTIBODIES
5.1.1 OVERVIEW OF ANTIBODY PRODUCTION
5.1.1.1 In-house vs. Outsourced:
5.1.2 ANTIBODY PRICING FACTORS
5.2 LINKERS
5.2.1 ROLE AND TYPES OF LINKERS
5.2.1.1 Cost Impact by Linker Type:
5.3 CYTOTOXIC AGENTS
5.3.1 COST CONSIDERATIONS:
5.3.2 BUFFERS AND SOLVENTS
5.4 COST BREAKDOWN BY MANUFACTURING STAGE
5.4.1 PRE-PRODUCTION COSTS
5.4.2 CONJUGATION PROCESS
5.4.3 PURIFICATION AND FILTRATION
5.4.4 QUALITY CONTROL
5.5 COST PROJECTIONS AND PRICING TRENDS (2024–2030)
5.5.1 PROJECTED COST FLUCTUATIONS
5.5.2 COST IMPACT OF SCALABILITY
5.6 SUPPLIER AND GEOGRAPHIC PRICING TRENDS
5.6.1 GEOGRAPHIC COST VARIATIONS
5.6.2 SUPPLIER ANALYSIS
5.6.3 CONCLUSION
6 NORTH AMERICA ANTIBODY DRUG CONJUGATES (ADC) MARKET: REGULATIONS
7 MARKET OVERVIEW
7.1 DRIVERS
7.1.1 INCREASING PREVALENCE OF CANCER
7.1.2 ADVANCES IN ANTIBODY-DRUG CONJUGATE (ADC) TECHNOLOGY
7.1.3 INCREASING DEMAND FOR TARGETED THERAPIES
7.1.4 ADVANCEMENTS IN PROTEOMICS AND GENOMICS RESEARCH
7.2 RESTRAINTS
7.2.1 HIGH DEVELOPMENT COST & MANUFACTURING COMPLEXITIES
7.2.2 SAFETY AND TOXICITY ISSUES OF ANTIBODY DRUG CONJUGATES
7.3 OPPORTUNITIES
7.3.1 GROWING ONCOLOGY PIPELINE FOR ANTIBODY DRUG CONJUGATES (ADCS)
7.3.2 INCREASING INVESTMENT IN CANCER RESEARCH
7.3.3 INCREASING COLLABORATION WITH RESEARCH INSTITUTIONS FOR ANTIBODY DRUG CONJUGATES
7.4 CHALLENGES
7.4.1 CLINICAL TRIAL FAILURES FOR ANTIBODY DRUG CONJUGATES DEVELOPMENT
7.4.2 LENGTHY CLINICAL TRIALS AND DEVELOPMENT PHASES
8 NORTH AMERICA ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY PRODUCT
8.1 OVERVIEW
8.2 ENHERTU
8.3 KADCYLA
8.4 TRODELVY
8.5 POLIVY
8.6 ADCETRIS
8.7 PADCEV
8.8 BESPONSA
8.9 ELAHERE
8.1 ZYLONTA
8.11 MYLOTARG
8.12 TIVDAK
8.13 OTHERS
9 NORTH AMERICA ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY ANTIGEN COMPONENT
9.1 OVERVIEW
9.2 HER2 RECEPTOR
9.3 TROP-2
9.4 CD79B
9.5 CD30
9.6 NECTIN 4
9.7 CD22
9.8 CD19
9.9 CD33
9.1 TISSUE FACTORS
9.11 OTHERS
10 NORTH AMERICA ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY ANTIBODY COMPONENT
10.1 OVERVIEW
10.2 THIRD GENERATION ADCS
10.3 SECOND GENERATION ADCS
10.4 FOURTH GENERATION ADCS
10.5 FIRST GENERATION ADCS
11 NORTH AMERICA ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY LINKERS COMPONENT
11.1 OVERVIEW
11.2 CLEAVABLE LINKERS
11.2.1 PEPTIDE BASED
11.2.2 ACID SENSITIVE OR ACID LABILE
11.2.3 GLUTATHIONE SENSITIVE DISULFIDE
11.3 NON CLEAVABLE LINKERS
12 NORTH AMERICA ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY CYTOTOXIC PAYLOADS OR WARHEADS COMPONENT
12.1 OVERVIEW
12.2 DNA DAMAGING AGENTS
12.2.1 CAMPTOTHECIN
12.2.2 CALICHEAMICIN
12.2.3 PYRROLOBENZODIAZEPINES
12.3 MICROTUBULE DISRUPTING AGENTS
12.3.1 AURISTATIN
12.3.2 MAYTANSINOIDS
13 NORTH AMERICA ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY LINKER TECHNOLOGY
13.1 OVERVIEW
13.2 PEPTIDE LINKERS
13.3 THIOETHER LINKERS
13.4 HYDRAZONE LINKERS
13.5 DISULFIDE LINKERS
14 NORTH AMERICA ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY CONJUGATION TECHNOLOGY
14.1 OVERVIEW
14.2 SITE-SPECIFIC CONJUGATION
14.3 CHEMICAL CONJUGATION
15 NORTH AMERICA ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY INDICATION
15.1 OVERVIEW
15.2 BREAST CANCER
15.3 BLOOD CANCER (LEUKEMIA, LYMPHOMA)
15.4 LUNG CANCER
15.5 GYNECOLOGICAL CANCER
15.6 GASTROINTESTINAL CANCER
15.7 GENITOURINARY CANCER
15.8 OTHERS
16 NORTH AMERICA ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY END USER
16.1 OVERVIEW
16.2 HOSPITALS
16.3 SPECIALTY CENTER
16.4 CLINICS
16.5 AMBULATORY CENTERS
16.6 HOME HEALTHCARE
16.7 OTHERS
17 NORTH AMERICA ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY DISTRIBUTION CHANNEL
17.1 OVERVIEW
17.2 DIRECT TENDERS
17.3 RETAIL SALES
17.3.1 HOSPITAL PHARMACY
17.3.2 RETAIL PHARMACY
17.3.3 ONLINE PHARMACY
17.4 OTHERS
18 NORTH AMERICA ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY REGION
18.1 NORTH AMERICA
18.1.1 U.S
18.1.2 CANADA
18.1.3 MEXICO
19 NORTH AMERICA ANTIBODY DRUG CONJUGATES (ADC): COMPANY LANDSCAPE
19.1 COMPANY SHARE ANALYSIS: NORTH AMERICA
20 SWOT ANALYSIS
21 COMPANY PROFILES
21.1 DAIICHI SANKYO, INC.
21.1.1 COMPANY SNAPSHOT
21.1.2 REVENUE ANALYSIS
21.1.3 PRODUCT PORTFOLIO
21.1.4 RECENT DEVELOPMENT
21.2 F. HOFFMANN-LA ROCHE LTD
21.2.1 COMPANY SNAPSHOT
21.2.2 REVENUE ANALYSIS
21.2.3 PRODUCT PORTFOLIO
21.2.4 RECENT DEVELOPMENT
21.3 GILEAD SCIENCES, INC.
21.3.1 COMPANY SNAPSHOT
21.3.2 REVENUE
21.3.3 PRODUCT PORTFOLIO
21.3.4 RECENT DEVELOPMENT
21.4 ASTELLAS PHARMA INC.
21.4.1 COMPANY SNAPSHOT
21.4.2 REVENUE ANALYSIS
21.4.3 PRODUCT PORTFOLIO
21.4.4 RECENT DEVELOPMENT
21.5 TAKEDA PHARMACEUTICAL COMPANY LIMITED
21.5.1 COMPANY SNAPSHOT
21.5.2 REVENUE ANALYSIS
21.5.3 PRODUCT PORTFOLIO
21.5.4 RECENT DEVELOPMENT
21.6 ABBVIE INC.
21.6.1 COMPANY SNAPSHOT
21.6.2 REVENUE
21.6.3 PRODUCT PORTFOLIO
21.6.4 RECENT DEVELOPMENT
21.7 ADC THERAPEUTICS SA
21.7.1 6.1 COMPANY SNAPSHOT
21.7.2 REVENUE ANALYSIS
21.7.3 PRODUCT PORTFOLIO
21.7.4 RECENT DEVELOPMENT
21.8 AMGEN, INC.
21.8.1 COMPANY SNAPSHOT
21.8.2 REVENUE ANALYSIS
21.8.3 PRODUCT PORTFOLIO
21.8.4 RECENT DEVELOPMENT
21.9 ASTRAZENECA
21.9.1 COMPANY SNAPSHOT
21.9.2 REVENUE ANALYSIS
21.9.3 PRODUCT PORTFOLIO
21.9.4 RECENT DEVELOPMENT
21.1 BAYER
21.10.1 COMPANY SNAPSHOT
21.10.2 REVENUE ANALYSIS
21.10.3 PRODUCT PORTFOLIO
21.10.4 RECENT DEVELOPMENT
21.11 BYONDIS
21.11.1 COMPANY SNAPSHOT
21.11.2 PRODUCT PORTFOLIO
21.11.3 RECENT DEVELOPMENT
21.12 EISAI INC
21.12.1 COMPANY SNAPSHOT
21.12.2 REVENUE ANALYSIS
21.12.3 PRODUCT PORTFOLIO
21.12.4 RECENT DEVELOPMENT
21.13 GSK PLC
21.13.1 COMPANY SNAPSHOT
21.13.2 REVENUE ANALYSIS
21.13.3 PRODUCT PORTFOLIO
21.13.4 RECENT DEVELOPMENT
21.14 JOHNSON & JOHNSON SERVICES, INC.
21.14.1 COMPANY SNAPSHOT
21.14.2 REVENUE ANALYSIS
21.14.3 PRODUCT PORTFOLIO
21.14.4 RECENT DEVELOPMENT
21.15 OXFORD BIOTHERAPEUTICS
21.15.1 COMPANY SNAPSHOT
21.15.2 PRODUCT PORTFOLIO
21.15.3 RECENT DEVELOPMENT
21.16 PFIZER INC.
21.16.1 COMPANY SNAPSHOT
21.16.2 REVENUE ANALYSIS
21.16.3 PRODUCT PORTFOLIO
21.16.4 RECENT UPDATES
21.17 REMEGEN
21.17.1 COMPANY SNAPSHOT
21.17.2 PRODUCT PORTFOLIO
21.17.3 RECENT DEVELOPMENTS
21.18 SANOFI
21.18.1 COMPANY SNAPSHOT
21.18.2 REVENUE ANALYSIS
21.18.3 PRODUCT PORTFOLIO
21.18.4 RECENT DEVELOPMENT
21.19 SUTRO BIOPHARMA, INC.
21.19.1 COMPANY SNAPSHOT
21.19.2 REVENUE ANALYSIS
21.19.3 PRODUCT PORTFOLIO
21.19.4 RECENT UPDATES
22 QUESTIONNAIRE
23 RELATED REPORTS
表格列表
TABLE 1 PROJECTED PRICE CHANGE (2024–2030)
TABLE 2 NORTH AMERICA ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY PRODUCT, 2022-2031 (USD MILLION)
TABLE 3 NORTH AMERICA ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY PRODUCT, 2022-2031 (VOLUME IN UNITS)
TABLE 4 NORTH AMERICA ENHERTU IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 5 NORTH AMERICA KADCYLA IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 6 NORTH AMERICA TRODELVY IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 7 NORTH AMERICA POLIVY IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 8 NORTH AMERICA ADCETRIS IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 9 NORTH AMERICA PADCEV IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 10 NORTH AMERICA BESPONSA IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 11 NORTH AMERICA ELAHERE IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 12 NORTH AMERICA ZYLONTA IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 13 NORTH AMERICA MYLOTARG IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 14 NORTH AMERICA TIVDAK IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 15 NORTH AMERICA OTHERS IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 16 NORTH AMERICA ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY ANTIGEN COMPONENT, 2022-2031 (USD MILLION)
TABLE 17 NORTH AMERICA HER2 RECEPTOR IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 18 NORTH AMERICA TROP-2 IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 19 NORTH AMERICA CD79B IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 20 NORTH AMERICA CD30 IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 21 NORTH AMERICA NECTIN 4 IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 22 NORTH AMERICA CD22 IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 23 NORTH AMERICA CD19 IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 24 NORTH AMERICA CD33 IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 25 NORTH AMERICA TISSUE FACTORS IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 26 NORTH AMERICA OTHERS IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 27 NORTH AMERICA ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY ANTIBODY COMPONENT, 2022-2031 (USD MILLION)
TABLE 28 NORTH AMERICA THIRD GENERATION ADCS IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 29 NORTH AMERICA SECOND GENERATION ADCS IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 30 NORTH AMERICA FOURTH GENERATION ADCS IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 31 NORTH AMERICA FIRST GENERATION ADCS IN OPHTHALMOLOGY MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 32 NORTH AMERICA ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY LINKERS COMPONENT, 2022-2031 (USD MILLION)
TABLE 33 NORTH AMERICA CLEAVABLE LINKERS IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 34 NORTH AMERICA CLEAVABLE LINKERS IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY COMPONENT, 2022-2031 (USD MILLION)
TABLE 35 NORTH AMERICA NON CLEAVABLE LINKERS IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 36 NORTH AMERICA ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY CYTOTOXIC PAYLOADS OR WARHEADS COMPONENT, 2022-2031 (USD MILLION)
TABLE 37 NORTH AMERICA DNA DAMAGING AGENTS IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 38 NORTH AMERICA DNA DAMAGING AGENTS IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY COMPONENT, 2022-2031 (USD MILLION)
TABLE 39 NORTH AMERICA MICROTUBULE DISRUPTING AGENTS IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 40 NORTH AMERICA MICROTUBULE DISRUPTING AGENTS IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY COMPONENT, 2022-2031 (USD MILLION)
TABLE 41 NORTH AMERICA ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY LINKER TECHNOLOGY, 2022-2031 (USD MILLION)
TABLE 42 NORTH AMERICA PEPTIDE LINKERS IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 43 NORTH AMERICA THIOETHER LINKERS IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 44 NORTH AMERICA HYDRAZONE LINKERS IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 45 NORTH AMERICA DISULFIDE LINKERS IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 46 NORTH AMERICA ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY CONJUGATION TECHNOLOGY, 2022-2031 (USD MILLION)
TABLE 47 NORTH AMERICA SITE-SPECIFIC CONJUGATION IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 48 NORTH AMERICA CHEMICAL CONJUGATION IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 49 NORTH AMERICA ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY INDICATION, 2022-2031 (USD MILLION)
TABLE 50 NORTH AMERICA BREAST CANCER IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 51 NORTH AMERICA BLOOD CANCER (LEUKEMIA, LYMPHOMA) IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 52 NORTH AMERICA LUNG CANCER IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 53 NORTH AMERICA GYNECOLOGICAL CANCER IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 54 NORTH AMERICA GASTROINTESTINAL CANCER IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 55 NORTH AMERICA GENITOURINARY CANCER IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 56 NORTH AMERICA OTHERS IN OPHTHALMOLOGY MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 57 NORTH AMERICA ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 58 NORTH AMERICA HOSPITALS IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 59 NORTH AMERICA SPECIALTY CENTERS IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 60 NORTH AMERICA CLINICS IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 61 NORTH AMERICA AMBULATORY CENTERS IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 62 NORTH AMERICA HOME HEALTHCARE IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 63 NORTH AMERICA OTHERS IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 64 NORTH AMERICA ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 65 NORTH AMERICA DIRECT TENDERS IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 66 NORTH AMERICA RETAIL SALES IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 67 NORTH AMERICA RETAIL SALES IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 68 NORTH AMERICA OTHERS IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 69 NORTH AMERICA ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY COUNTRY, 2022-2031 (USD MILLION)
TABLE 70 NORTH AMERICA ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY PRODUCT, 2022-2031 (USD MILLION)
TABLE 71 NORTH AMERICA ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY PRODUCT, 2022-2031 (VOLUME IN UNITS)
TABLE 72 NORTH AMERICA ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY PRODUCT, 2022-2031 (ASP)
TABLE 73 NORTH AMERICA ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY ANTIGEN COMPONENT, 2022-2031 (USD MILLION)
TABLE 74 NORTH AMERICA ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY ANTIBODY COMPONENT, 2022-2031 (USD MILLION)
TABLE 75 NORTH AMERICA ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY LINKERS COMPONENT, 2022-2031 (USD MILLION)
TABLE 76 NORTH AMERICA CLEAVABLE LINKERS IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY LINKERS COMPONENT, 2022-2031 (USD MILLION)
TABLE 77 NORTH AMERICA ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY CYTOTOXIC PAYLOADS OR WARHEADS COMPONENT, 2022-2031 (USD MILLION)
TABLE 78 NORTH AMERICA DNA DAMAGING AGENTS IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY CYTOTOXIC PAYLOADS OR WARHEADS COMPONENT, 2022-2031 (USD MILLION)
TABLE 79 NORTH AMERICA MICROTUBULE DISRUPTING AGENTS IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY CYTOTOXIC PAYLOADS OR WARHEADS COMPONENT, 2022-2031 (USD MILLION)
TABLE 80 NORTH AMERICA ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY LINKER TECHNOLOGY, 2022-2031 (USD MILLION)
TABLE 81 NORTH AMERICA ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY CONJUGATION TECHNOLOGY, 2022-2031 (USD MILLION)
TABLE 82 NORTH AMERICA ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY INDICATION, 2022-2031 (USD MILLION)
TABLE 83 NORTH AMERICA ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 84 NORTH AMERICA ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 85 NORTH AMERICA RETAIL SALES IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 86 U.S. ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY PRODUCT, 2022-2031 (USD MILLION)
TABLE 87 U.S. ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY PRODUCT, 2022-2031 (VOLUME IN UNITS)
TABLE 88 U.S. ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY PRODUCT, 2022-2031 (ASP)
TABLE 89 U.S. ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY ANTIGEN COMPONENT, 2022-2031 (USD MILLION)
TABLE 90 U.S. ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY ANTIBODY COMPONENT, 2022-2031 (USD MILLION)
TABLE 91 U.S. ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY LINKERS COMPONENT, 2022-2031 (USD MILLION)
TABLE 92 U.S. CLEAVABLE LINKERS IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY COMPONENT, 2022-2031 (USD MILLION)
TABLE 93 U.S. ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY CYTOTOXIC PAYLOADS OR WARHEADS COMPONENT, 2022-2031 (USD MILLION)
TABLE 94 U.S. DNA DAMAGING AGENTS IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY COMPONENT, 2022-2031 (USD MILLION)
TABLE 95 U.S. MICROTUBULE DISRUPTING AGENTS IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY COMPONENT, 2022-2031 (USD MILLION)
TABLE 96 U.S. ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY LINKER TECHNOLOGY, 2022-2031 (USD MILLION)
TABLE 97 U.S. ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY CONJUGATION TECHNOLOGY, 2022-2031 (USD MILLION)
TABLE 98 U.S. ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY INDICATION, 2022-2031 (USD MILLION)
TABLE 99 U.S. ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 100 U.S. ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 101 U.S. RETAIL SALES IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 102 CANADA ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY PRODUCT, 2022-2031 (USD MILLION)
TABLE 103 CANADA ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY PRODUCT, 2022-2031 (VOLUME IN UNITS)
TABLE 104 CANADA ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY PRODUCT, 2022-2031 (ASP)
TABLE 105 CANADA ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY ANTIGEN COMPONENT, 2022-2031 (USD MILLION)
TABLE 106 CANADA ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY ANTIBODY COMPONENT, 2022-2031 (USD MILLION)
TABLE 107 CANADA ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY LINKERS COMPONENT, 2022-2031 (USD MILLION)
TABLE 108 CANADA CLEAVABLE LINKERS IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY COMPONENT, 2022-2031 (USD MILLION)
TABLE 109 CANADA ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY CYTOTOXIC PAYLOADS OR WARHEADS COMPONENT, 2022-2031 (USD MILLION)
TABLE 110 CANADA DNA DAMAGING AGENTS IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY COMPONENT, 2022-2031 (USD MILLION)
TABLE 111 CANADA MICROTUBULE DISRUPTING AGENTS IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY COMPONENT, 2022-2031 (USD MILLION)
TABLE 112 CANADA ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY LINKER TECHNOLOGY, 2022-2031 (USD MILLION)
TABLE 113 CANADA ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY CONJUGATION TECHNOLOGY, 2022-2031 (USD MILLION)
TABLE 114 CANADA ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY INDICATION, 2022-2031 (USD MILLION)
TABLE 115 CANADA ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 116 CANADA ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 117 CANADA RETAIL SALES IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 118 MEXICO ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY PRODUCT, 2022-2031 (USD MILLION)
TABLE 119 MEXICO ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY PRODUCT, 2022-2031 (VOLUME IN UNITS)
TABLE 120 MEXICO ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY PRODUCT, 2022-2031 (ASP)
TABLE 121 MEXICO ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY ANTIGEN COMPONENT, 2022-2031 (USD MILLION)
TABLE 122 MEXICO ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY ANTIBODY COMPONENT, 2022-2031 (USD MILLION)
TABLE 123 MEXICO ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY LINKERS COMPONENT, 2022-2031 (USD MILLION)
TABLE 124 MEXICO CLEAVABLE LINKERS IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY COMPONENT, 2022-2031 (USD MILLION)
TABLE 125 MEXICO ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY CYTOTOXIC PAYLOADS OR WARHEADS COMPONENT, 2022-2031 (USD MILLION)
TABLE 126 MEXICO DNA DAMAGING AGENTS IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY COMPONENT, 2022-2031 (USD MILLION)
TABLE 127 MEXICO MICROTUBULE DISRUPTING AGENTS IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY COMPONENT, 2022-2031 (USD MILLION)
TABLE 128 MEXICO ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY LINKER TECHNOLOGY, 2022-2031 (USD MILLION)
TABLE 129 MEXICO ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY CONJUGATION TECHNOLOGY, 2022-2031 (USD MILLION)
TABLE 130 MEXICO ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY INDICATION, 2022-2031 (USD MILLION)
TABLE 131 MEXICO ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 132 MEXICO ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 133 MEXICO RETAIL SALES IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
图片列表
FIGURE 1 NORTH AMERICA ANTIBODY DRUG CONJUGATES (ADC) MARKET: SEGMENTATION
FIGURE 2 NORTH AMERICA ANTIBODY DRUG CONJUGATES (ADC) MARKET: DATA TRIANGULATION
FIGURE 3 NORTH AMERICA ANTIBODY DRUG CONJUGATES (ADC) MARKET: DROC ANALYSIS
FIGURE 4 NORTH AMERICA ANTIBODY DRUG CONJUGATES (ADC) MARKET: NORTH AMERICA VS REGIONAL MARKET ANALYSIS
FIGURE 5 NORTH AMERICA ANTIBODY DRUG CONJUGATES (ADC) MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 NORTH AMERICA ANTIBODY DRUG CONJUGATES (ADC) MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 7 NORTH AMERICA ANTIBODY DRUG CONJUGATES (ADC) MARKET: MARKET APPLICATION COVERAGE GRID
FIGURE 8 NORTH AMERICA ANTIBODY DRUG CONJUGATES (ADC) MARKET: DBMR MARKET POSITION GRID
FIGURE 9 NORTH AMERICA ANTIBODY DRUG CONJUGATES (ADC) MARKET: VENDOR SHARE ANALYSIS
FIGURE 10 NORTH AMERICA ANTIBODY DRUG CONJUGATES (ADC) MARKET: SEGMENTATION
FIGURE 11 EXECUTIVE SUMMARY
FIGURE 12 STRATEGIC DECISIONS
FIGURE 13 RISING INCIDENCE OF CANCER IS DRIVING THE GROWTH OF THE NORTH AMERICA ANTIBODY DRUG CONJUGATES (ADC) MARKET FROM 2024 TO 2031
FIGURE 14 THE PRODUCT SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE NORTH AMERICA ANTIBODY DRUG CONJUGATES (ADC) MARKET IN 2024 AND 2031
FIGURE 15 DROC
FIGURE 16 NORTH AMERICA ANTIBODY DRUG CONJUGATES (ADC) MARKET: BY PRODUCT, 2023
FIGURE 17 NORTH AMERICA ANTIBODY DRUG CONJUGATES (ADC) MARKET: BY PRODUCT, 2024-2031 (USD MILLION)
FIGURE 18 NORTH AMERICA ANTIBODY DRUG CONJUGATES (ADC) MARKET: BY PRODUCT, CAGR (2024-2031)
FIGURE 19 NORTH AMERICA ANTIBODY DRUG CONJUGATES (ADC) MARKET: BY PRODUCT, LIFELINE CURVE
FIGURE 20 NORTH AMERICA ANTIBODY DRUG CONJUGATES (ADC) MARKET: BY ANTIGEN COMPONENT, 2023
FIGURE 21 NORTH AMERICA ANTIBODY DRUG CONJUGATES (ADC) MARKET: BY ANTIGEN COMPONENT, 2024-2031 (USD MILLION)
FIGURE 22 NORTH AMERICA ANTIBODY DRUG CONJUGATES (ADC) MARKET: BY ANTIGEN COMPONENT, CAGR (2024-2031)
FIGURE 23 NORTH AMERICA ANTIBODY DRUG CONJUGATES (ADC) MARKET: BY ANTIGEN COMPONENT, LIFELINE CURVE
FIGURE 24 NORTH AMERICA ANTIBODY DRUG CONJUGATES (ADC) MARKET: BY ANTIBODY COMPONENT, 2023
FIGURE 25 NORTH AMERICA ANTIBODY DRUG CONJUGATES (ADC) MARKET: BY ANTIBODY COMPONENT, 2024-2031 (USD MILLION)
FIGURE 26 NORTH AMERICA ANTIBODY DRUG CONJUGATES (ADC) MARKET: BY ANTIBODY COMPONENT, CAGR (2024-2031)
FIGURE 27 NORTH AMERICA ANTIBODY DRUG CONJUGATES (ADC) MARKET: BY ANTIBODY COMPONENT, LIFELINE CURVE
FIGURE 28 NORTH AMERICA ANTIBODY DRUG CONJUGATES (ADC) MARKET: BY LINKERS COMPONENT, 2023
FIGURE 29 NORTH AMERICA ANTIBODY DRUG CONJUGATES (ADC) MARKET: BY LINKERS COMPONENT, 2024-2031 (USD MILLION)
FIGURE 30 NORTH AMERICA ANTIBODY DRUG CONJUGATES (ADC) MARKET: BY LINKERS COMPONENT, CAGR (2024-2031)
FIGURE 31 NORTH AMERICA ANTIBODY DRUG CONJUGATES (ADC) MARKET: BY LINKERS COMPONENT, LIFELINE CURVE
FIGURE 32 NORTH AMERICA ANTIBODY DRUG CONJUGATES (ADC) MARKET: BY CYTOTOXIC PAYLOADS OR WARHEADS COMPONENT, 2023
FIGURE 33 NORTH AMERICA ANTIBODY DRUG CONJUGATES (ADC) MARKET: BY CYTOTOXIC PAYLOADS OR WARHEADS COMPONENT, 2024-2031 (USD MILLION)
FIGURE 34 NORTH AMERICA ANTIBODY DRUG CONJUGATES (ADC) MARKET: BY CYTOTOXIC PAYLOADS OR WARHEADS COMPONENT, CAGR (2024-2031)
FIGURE 35 NORTH AMERICA ANTIBODY DRUG CONJUGATES (ADC) MARKET: BY CYTOTOXIC PAYLOADS OR WARHEADS COMPONENT, LIFELINE CURVE
FIGURE 36 NORTH AMERICA ANTIBODY DRUG CONJUGATES (ADC) MARKET: BY LINKER TECHNOLOGY, 2023
FIGURE 37 NORTH AMERICA ANTIBODY DRUG CONJUGATES (ADC) MARKET: BY LINKER TECHNOLOGY, 2024-2031 (USD MILLION)
FIGURE 38 NORTH AMERICA ANTIBODY DRUG CONJUGATES (ADC) MARKET: BY LINKER TECHNOLOGY, CAGR (2024-2031)
FIGURE 39 NORTH AMERICA ANTIBODY DRUG CONJUGATES (ADC) MARKET: BY LINKER TECHNOLOGY, LIFELINE CURVE
FIGURE 40 NORTH AMERICA ANTIBODY DRUG CONJUGATES (ADC) MARKET: BY CONJUGATION TECHNOLOGY, 2023
FIGURE 41 NORTH AMERICA ANTIBODY DRUG CONJUGATES (ADC) MARKET: BY CONJUGATION TECHNOLOGY, 2024-2031 (USD MILLION)
FIGURE 42 NORTH AMERICA ANTIBODY DRUG CONJUGATES (ADC) MARKET: BY CONJUGATION TECHNOLOGY, CAGR (2024-2031)
FIGURE 43 NORTH AMERICA ANTIBODY DRUG CONJUGATES (ADC) MARKET: BY CONJUGATION TECHNOLOGY, LIFELINE CURVE
FIGURE 44 NORTH AMERICA ANTIBODY DRUG CONJUGATES (ADC) MARKET: BY INDICATION, 2023
FIGURE 45 NORTH AMERICA ANTIBODY DRUG CONJUGATES (ADC) MARKET: BY INDICATION, 2024-2031 (USD MILLION)
FIGURE 46 NORTH AMERICA ANTIBODY DRUG CONJUGATES (ADC) MARKET: BY INDICATION, CAGR (2024-2031)
FIGURE 47 NORTH AMERICA ANTIBODY DRUG CONJUGATES (ADC) MARKET: BY INDICATION, LIFELINE CURVE
FIGURE 48 NORTH AMERICA ANTIBODY DRUG CONJUGATES (ADC) MARKET: BY END USER, 2023
FIGURE 49 NORTH AMERICA ANTIBODY DRUG CONJUGATES (ADC) MARKET: BY END USER, 2024-2031 (USD MILLION)
FIGURE 50 NORTH AMERICA ANTIBODY DRUG CONJUGATES (ADC) MARKET: BY END USER, CAGR (2024-2031)
FIGURE 51 NORTH AMERICA ANTIBODY DRUG CONJUGATES (ADC) MARKET: BY END USER, LIFELINE CURVE
FIGURE 52 NORTH AMERICA ANTIBODY DRUG CONJUGATES (ADC) MARKET: BY DISTRIBUTION CHANNEL, 2023
FIGURE 53 NORTH AMERICA ANTIBODY DRUG CONJUGATES (ADC) MARKET: BY DISTRIBUTION CHANNEL, 2024-2031 (USD MILLION)
FIGURE 54 NORTH AMERICA ANTIBODY DRUG CONJUGATES (ADC) MARKET: BY DISTRIBUTION CHANNEL, CAGR (2024-2031)
FIGURE 55 NORTH AMERICA ANTIBODY DRUG CONJUGATES (ADC) MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE
FIGURE 56 NORTH AMERICA ANTIBODY DRUG CONJUGATES (ADC) MARKET: SNAPSHOT (2023)
FIGURE 57 NORTH AMERICA ANTIBODY DRUG CONJUGATES (ADC): COMPANY SHARE 2023 (%)
研究方法
数据收集和基准年分析是使用具有大样本量的数据收集模块完成的。该阶段包括通过各种来源和策略获取市场信息或相关数据。它包括提前检查和规划从过去获得的所有数据。它同样包括检查不同信息源中出现的信息不一致。使用市场统计和连贯模型分析和估计市场数据。此外，市场份额分析和关键趋势分析是市场报告中的主要成功因素。要了解更多信息，请请求分析师致电或下拉您的询问。
DBMR 研究团队使用的关键研究方法是数据三角测量，其中包括数据挖掘、数据变量对市场影响的分析和主要（行业专家）验证。数据模型包括供应商定位网格、市场时间线分析、市场概览和指南、公司定位网格、专利分析、定价分析、公司市场份额分析、测量标准、全球与区域和供应商份额分析。要了解有关研究方法的更多信息，请向我们的行业专家咨询。
可定制
Data Bridge Market Research 是高级形成性研究领域的领导者。我们为向现有和新客户提供符合其目标的数据和分析而感到自豪。报告可定制，包括目标品牌的价格趋势分析、了解其他国家的市场（索取国家列表）、临床试验结果数据、文献综述、翻新市场和产品基础分析。目标竞争对手的市场分析可以从基于技术的分析到市场组合策略进行分析。我们可以按照您所需的格式和数据样式添加您需要的任意数量的竞争对手数据。我们的分析师团队还可以为您提供原始 Excel 文件数据透视表（事实手册）中的数据，或者可以帮助您根据报告中的数据集创建演示文稿。
